Early treatment response evaluation using FET PET compared to MRI in glioblastoma patients at first progression treated with bevacizumab plus lomustine.
Norbert GalldiksVeronika DunklGarry CecconCaroline TscherpelGabriele StoffelsIan LawOtto M HenriksenAida MuhicHans S PoulsenJan StegerElena K BauerPhilipp LohmannMatthias SchmidtNadim J ShahGereon R FinkKarl-Josef LangenPublished in: European journal of nuclear medicine and molecular imaging (2018)
FET-PET appears to be useful for identifying responders to BEV/LOM early after treatment initiation.